Non-interventional study to collect real-world clinical and patient-reported outcomes in ovarian cancer - SCOUT-1

Inclusion Criteria

• 1. Signed written informed consent
• 2. Women aged ≥ 18 years
• 3. Newly diagnosed with primary advanced (FIGO stages III and IV) high-grade epithelial ovarian cancer (including fallopian tube and/or primary peritoneal cancer)
• 4. For patients who qualify for primary debulking surgery, all surgical procedures must be completed prior to enrollment
• 5. BRCA mutation test (routinely analyzed germline and/or somatic BRCA1/2 status alone or as part of HRD status determination) already performed or initiated/intended
• 6. First-line platinum-based chemotherapy planned or a maximum of 3 cycles already received with no sign of disease progression. Total number of cycles after enrollment should be decided individually for each single patient by the treating physician. In case of neoadjuvant chemotherapy and interval debulking surgery, the patient should be enrolled after completion of surgical procedure and at the time of the 1st post-surgery cycle of platinum-based chemotherapy.
• 7. Willing and able to report PROs electronically
• 8. Women of childbearing potential must use two forms of reliable contraception according to standard of care